IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, has long lacked effective targeted therapies. Recently, an innovative therapy named BHV-1400 has demonstrated striking potential in animal studies. Acting like a “biological missile,” it precisely targets and eliminates key pathogenic proteins responsible for kidney damage. The latest research shows that this drug can reduce pathogenic protein levels by 58% with rapid onset of action. How is this achieved? Let us take a closer look.
The core pathogenic mechanism of IgAN is closely associated with the abnormal deposition of galactose-deficient IgA1 (Gd-IgA1) and its immune complexes. In genetically susceptible individuals, dysfunction of B-cell glycosyltransferases leads to the production of galactose-deficient IgA1 (Gd-IgA1). These aberrant IgA1 molecules are recognized by autoantibodies to form immune complexes, which deposit in the glomerular mesangial region, activate the complement system (especially the MBL pathway), and trigger inflammatory responses. This ultimately results in mesangial cell proliferation, matrix expansion, and progressive renal injury.
BHV-1400 is an antibody-based bifunctional conjugate. Its unique design includes one targeting arm that specifically recognizes and binds pathogenic circulating Gd-IgA1 and Gd-IgA1–IgG immune complexes, and another navigation arm that enables precise targeting via the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes. Through hepatocyte-mediated internalization, the pathogenic proteins are taken up and degraded, achieving efficient clearance. BHV-1400 cleverly leverages the liver’s natural clearance mechanisms to precisely recognize, directionally transport, and ultimately degrade pathogenic proteins through the powerful lysosomal system of hepatocytes.
In cellular and rodent studies, BHV-1400 has demonstrated compelling preclinical evidence of rapid and potent degradation of deglycosylated IgA and related protein aggregates. In vivo studies in mice administered exogenous dg-IgA showed that BHV-1400 significantly cleared exogenous dg-IgA via an ASGPR-dependent mechanism. In wild-type mice, dosing at a 2:1 ratio (drug:target) reduced dg-IgA levels by 58%, whereas no such effect was observed in ASGPR1 knockout mice or with the parental antibody BH5305, confirming the specificity and high efficiency of its targeted clearance.
The ASGPR protein is encoded by the asialoglycoprotein receptor 1 (ASGR1) gene and is a glycoprotein receptor primarily expressed on the hepatocyte membrane. It binds desialylated glycoproteins in the blood, internalizes them, and transports them to lysosomes for degradation. Studies have found that ASGR1-deficient variants are associated with lower cholesterol levels and reduced risk of cardiovascular disease. Research indicates that ASGR1 promotes cholesterol efflux into bile, which is subsequently excreted via feces, thereby reducing lipid levels in blood and liver and showing clear therapeutic effects in atherosclerosis and fatty liver disease. ASGR1 is currently emerging as a novel therapeutic target for hypercholesterolemia, demonstrating significant lipid-lowering and vascular protective effects.
Table 1 ASGR1-targeting drugs under development (Wisdom Engine)
To advance research in primary glomerular diseases, hepatitis, and cardiovascular diseases, Kyinno Biotechnology has constructed ASGR1 overexpression engineered cell lines. Using genetic engineering technologies, these cell lines achieve stable high-level expression of ASGR1 on the cell membrane. This innovation provides a powerful tool to support research into the pathogenesis of IgA nephropathy (IgAN) and the development of targeted therapies. The model accurately mimics the natural biological characteristics of ASGR1 receptors on the hepatocyte surface and is broadly applicable to drug screening, mechanistic studies, and therapeutic evaluation, and has already been applied in off-target validation studies. In addition to cell line construction services, our company also provides antibody discovery, antibody expression, antibody off-target screening, and in vivo and in vitro pharmacological testing services. Please contact us for more information.
The ASGR1 overexpression engineered cell lines are listed as follows:
- KC-4427 293T-ASGR1
- KC-4775 CHOK1-ASGR1
Validation data are shown below:
- KC-4427 293T-ASGR1
- KC-4775 CHOK1-ASGR1
